THERATECHNOLOGIES INC (THTX) Stock Price, Forecast & Analysis
USA - NASDAQ:THTX - CA88338H7040 - Common Stock
THTX Key Statistics, Chart & Performance
The current stock price of THTX is 3.39 USD. In the past month the price increased by 4.63%. In the past year, price increased by 171.2%.
THTX Latest News, Press Relases and Analysis
THTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About THTX
Company Profile
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The company is headquartered in Montreal, Quebec and currently employs 94 full-time employees. The firm offers prescription products for individuals with human immunodeficient virus (HIV) in the United States and its pipeline is focused on specialized therapies designed to address unmet medical needs in both HIV and oncology. The company markets two HIV products, namely EGRIFTA SV and Trogarzo; and has research programs in HIV and oncology. EGRIFTA SV is the therapy for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Trogarzo injection is used with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 who are failing their current regimen. Its pipeline includes Donidalorsen and Olezarsen, and the SORT1+ oncology platform. The firm is also focusing on tesamorelin life-cycle management in lipodystrophy.
Company Info
THERATECHNOLOGIES INC
2015 Peel Street, 11th Floor
MONTREAL QUEBEC H3A 1T8 CA
CEO: Paul Levesque
Employees: 103
Phone: 15143367800
THERATECHNOLOGIES INC / THTX FAQ
What does THTX do?
Theratechnologies, Inc. is a pharmaceutical company, which engages in addressing medical needs of patients with Human Immunodeficiency Virus (HIV). The company is headquartered in Montreal, Quebec and currently employs 94 full-time employees. The firm offers prescription products for individuals with human immunodeficient virus (HIV) in the United States and its pipeline is focused on specialized therapies designed to address unmet medical needs in both HIV and oncology. The company markets two HIV products, namely EGRIFTA SV and Trogarzo; and has research programs in HIV and oncology. EGRIFTA SV is the therapy for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. Trogarzo injection is used with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 who are failing their current regimen. Its pipeline includes Donidalorsen and Olezarsen, and the SORT1+ oncology platform. The firm is also focusing on tesamorelin life-cycle management in lipodystrophy.
What is the current price of THTX stock?
The current stock price of THTX is 3.39 USD.
Does THTX stock pay dividends?
THTX does not pay a dividend.
What is the ChartMill technical and fundamental rating of THTX stock?
THTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about THERATECHNOLOGIES INC (THTX) stock?
10 analysts have analysed THTX and the average price target is 4.09 USD. This implies a price increase of 20.63% is expected in the next year compared to the current price of 3.39.
What is THERATECHNOLOGIES INC worth?
THERATECHNOLOGIES INC (THTX) has a market capitalization of 155.87M USD. This makes THTX a Micro Cap stock.
THTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to THTX. When comparing the yearly performance of all stocks, THTX is one of the better performing stocks in the market, outperforming 96.37% of all stocks.
THTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to THTX. While THTX is still in line with the averages on profitability rating, there are concerns on its financial health.
THTX Financial Highlights
Over the last trailing twelve months THTX reported a non-GAAP Earnings per Share(EPS) of -0.19.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -17.86% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
THTX Forecast & Estimates
10 analysts have analysed THTX and the average price target is 4.09 USD. This implies a price increase of 20.63% is expected in the next year compared to the current price of 3.39.
For the next year, analysts expect an EPS growth of 88.56% and a revenue growth -3.03% for THTX